Nano-Hydroxyapatite-Derived Drug and Gene Co-Delivery System for Anti-Angiogenesis Therapy of Breast Cancer.

about

Nano-Hydroxyapatite-Derived Drug and Gene Co-Delivery System for Anti-Angiogenesis Therapy of Breast Cancer.

Item

http://www.wikidata.org/entity/Q42705465

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Nano-Hydroxyapatite-Derived Dr ...... esis Therapy of Breast Cancer.

@en

Nano-Hydroxyapatite-Derived Dr ...... esis Therapy of Breast Cancer.

@nl

type

Item

label

Nano-Hydroxyapatite-Derived Dr ...... esis Therapy of Breast Cancer.

@en

Nano-Hydroxyapatite-Derived Dr ...... esis Therapy of Breast Cancer.

@nl

prefLabel

Nano-Hydroxyapatite-Derived Dr ...... esis Therapy of Breast Cancer.

@en

Nano-Hydroxyapatite-Derived Dr ...... esis Therapy of Breast Cancer.

@nl

P1476

Nano-Hydroxyapatite-Derived Dr ...... nesis Therapy of Breast Cancer

@en

P2093

Lina Zhao

http://www.w3.org/2001/XMLSchema#string

Wenhui Zhao

http://www.w3.org/2001/XMLSchema#string

Xue Chen

http://www.w3.org/2001/XMLSchema#string

Yan Wang

http://www.w3.org/2001/XMLSchema#string

Ye Liu

http://www.w3.org/2001/XMLSchema#string

P2860

MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes

The biology of VEGF and its receptors

Angiogenesis in cancer and other diseases

Restoration of p53 function leads to tumour regression in vivo

Angiogenesis as a therapeutic target

Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells

New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis.

p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase.

A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy.

P304

4723-4732

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12659/MSM.902538

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28968380

http://www.w3.org/2001/XMLSchema#string

P932

5635948

http://www.w3.org/2001/XMLSchema#string